| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:WDFY2_LATS2 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: WDFY2_LATS2 | KinaseFusionDB ID: KFG7111 | FusionGDB2.0 ID: KFG7111 | Hgene | Tgene | Gene symbol | WDFY2 | LATS2 | Gene ID | 115825 | 26524 | |
| Gene name | WD repeat and FYVE domain containing 2 | large tumor suppressor kinase 2 | ||||||||||
| Synonyms | PROF|WDF2|ZFYVE22 | KPM | ||||||||||
| Cytomap | 13q14.3 | 13q12.11 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | WD repeat and FYVE domain-containing protein 2WD40 and FYVE domain containing 2WD40- and FYVE domain-containing protein 2propeller-FYVE proteinzinc finger FYVE domain-containing protein 22 | serine/threonine-protein kinase LATS2LATS (large tumor suppressor, Drosophila) homolog 2LATS, large tumor suppressor, homolog 2kinase phosphorylated during mitosis proteinlarge tumor suppressor homolog 2serine/threonine kinase KPMserine/threonine-pr | ||||||||||
| Modification date | 20240403 | 20240407 | ||||||||||
| UniProtAcc | Q96P53 | Q9NRM7 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000298125, ENST00000460145, | ENST00000382592, ENST00000472754, ENST00000542899, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: WDFY2 [Title/Abstract] AND LATS2 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | WDFY2(52333273)-LATS2(21573628), # samples:1 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | WDFY2 | GO:0001934 | positive regulation of protein phosphorylation | 17313651 |
| Tgene | LATS2 | GO:0000082 | G1/S transition of mitotic cell cycle | 12853976 |
| Tgene | LATS2 | GO:0006468 | protein phosphorylation | 10871863 |
| Tgene | LATS2 | GO:0009755 | hormone-mediated signaling pathway | 15131260 |
| Tgene | LATS2 | GO:0035329 | hippo signaling | 20412773 |
| Tgene | LATS2 | GO:0035556 | intracellular signal transduction | 10871863 |
| Tgene | LATS2 | GO:0045736 | negative regulation of cyclin-dependent protein serine/threonine kinase activity | 12853976 |
| Kinase Fusion gene breakpoints across WDFY2 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across LATS2 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChiTaRS5.0 | EC571358 | WDFY2 | chr13 | 52333273 | LATS2 | chr13 | 21573628 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:52333273/:21573628) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| WDFY2 | LATS2 |
| FUNCTION: Acts in an adapter protein-like fashion to mediate the interaction between the kinase PRKCZ and its substrate VAMP2 and increases the PRKCZ-dependent phosphorylation of VAMP2 (PubMed:17313651). Positively regulates adipocyte differentiation, by facilitating the phosphorylation and thus inactivation of the anti-adipogenetic transcription factor FOXO1 by the kinase AKT1 (PubMed:18388859). Plays a role in endosomal control of AKT2 signaling; required for insulin-stimulated AKT2 phosphorylation and glucose uptake and insulin-stimulated phosphorylation of AKT2 substrates (By similarity). Participates in transferrin receptor endocytosis (PubMed:16873553). {ECO:0000250|UniProtKB:Q8BUB4, ECO:0000269|PubMed:16873553, ECO:0000269|PubMed:17313651, ECO:0000269|PubMed:18388859}. | FUNCTION: Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS2 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in centrosome duplication, maintenance of mitotic fidelity and genomic stability. Negatively regulates G1/S transition by down-regulating cyclin E/CDK2 kinase activity. Negative regulator of the androgen receptor. Phosphorylates SNAI1 in the nucleus leading to its nuclear retention and stabilization, which enhances its epithelial-mesenchymal transition and tumor cell invasion/migration activities. This tumor-promoting activity is independent of its effects upon YAP1 or WWTR1/TAZ. {ECO:0000269|PubMed:10871863, ECO:0000269|PubMed:12853976, ECO:0000269|PubMed:15131260, ECO:0000269|PubMed:18158288, ECO:0000269|PubMed:21952048}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of WDFY2_LATS2 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| LATS2 | Q9NRM7 | human | YAP1 | P46937 | S397 | tyHSRDEstDsGLsM | |
| LATS2 | Q9NRM7 | human | CDKN1A | P38936 | S146 | GRkRRQtsMTDFyHs | |
| LATS2 | Q9NRM7 | human | SNAI2 | O43623 | T208 | QGHIRtHtGEkPFSC | |
| LATS2 | Q9NRM7 | human | MTF1 | Q14872 | S152 | EGCPRTysTAGNLRT | zf-C2H2 |
| LATS2 | Q9NRM7 | human | AMOTL2 | Q9Y2J4 | S159 | HGHVRsLsERLLQLs | |
| LATS2 | Q9NRM7 | human | YAP1 | P46937-2 | S109 | KsHsRQAstDAGtAG | |
| LATS2 | Q9NRM7 | human | YAP1 | P46937 | S127 | PQHVRAHssPAsLQL | |
| LATS2 | Q9NRM7 | human | YAP1 | P46937-2 | S127 | PQHVRAHssPASLQL | |
| LATS2 | Q9NRM7 | human | YAP1 | P46937 | S109 | ksHsRQAstDAGtAG | |
| LATS2 | Q9NRM7 | human | YAP1 | P46937-2 | S381 | TYHSRDEsTDsGLsM | |
| LATS2 | Q9NRM7 | human | WWTR1 | Q9GZV5 | S89 | AQHVRsHssPAsLQL | |
| LATS2 | Q9NRM7 | human | SNAI1 | O95863 | T203 | QGHVRtHtGEkPFSC | |
| LATS2 | Q9NRM7 | human | INCENP | Q9NQS7 | S894 | RYHKRtssAVWNsPP | |
| LATS2 | Q9NRM7 | human | ABL1 | P00519-2 | T197 | VYHYRINtASDGKLy | SH2 |
| LATS2 | Q9NRM7 | human | LATS2 | Q9NRM7 | S835 | GSHVRQDsMEPSDLW | Pkinase |
| LATS2 | Q9NRM7 | human | CDC26 | Q8NHZ8 | T7 | _MLRRKPtRLELKLD | ANAPC_CDC26 |
| LATS2 | Q9NRM7 | human | RPTOR | Q8N122 | S606 | SAHEkLYsLLSDPIP | HEAT |
| LATS2 | Q9NRM7 | human | PQBP1 | O60828 | S247 | FQQRPYPsPGAVLRA | |
| LATS2 | Q9NRM7 | human | YAP1 | P46937-2 | S61 | IVHVRGDsEtDLEAL | |
| LATS2 | Q9NRM7 | human | PRPS1 | P60891 | S285 | EDkMKHCsKIQVIDI | Pribosyl_synth |
| LATS2 | Q9NRM7 | human | YWHAG | P61981 | S59 | VVGARRSsWRVISsI | 14-3-3 |
| LATS2 | Q9NRM7 | human | KIF23 | Q02241 | S814 | LRHRRsRsAGDRWVD | MKLP1_Arf_bdg |
| LATS2 | Q9NRM7 | human | AMOT | Q4VCS5 | S175 | QGHVRSLsERLMQMS | |
| LATS2 | Q9NRM7 | human | KIF23 | Q02241 | S716 | QLHRRsNsCsSISVA | |
| LATS2 | Q9NRM7 | human | PRPS2 | P11908 | T285 | EDkMkHCtKIQVIDI | Pribosyl_synth |
| LATS2 | Q9NRM7 | human | YAP1 | P46937-2 | S164 | AQHLRQssFEIPDDV |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| LATS2 | ID | Description | 0.00e+00 |
| LATS2 | GO:0035329 | hippo signaling | 4.90e-07 |
| LATS2 | GO:0006469 | negative regulation of protein kinase activity | 2.93e-04 |
| LATS2 | GO:0033673 | negative regulation of kinase activity | 2.93e-04 |
| LATS2 | GO:0051348 | negative regulation of transferase activity | 4.57e-04 |
| LATS2 | GO:0008630 | intrinsic apoptotic signaling pathway in response to DNA damage | 4.57e-04 |
| LATS2 | GO:0016055 | Wnt signaling pathway | 4.57e-04 |
| LATS2 | GO:0198738 | cell-cell signaling by wnt | 4.57e-04 |
| LATS2 | GO:0002065 | columnar/cuboidal epithelial cell differentiation | 6.58e-04 |
| LATS2 | GO:0001933 | negative regulation of protein phosphorylation | 9.04e-04 |
| LATS2 | GO:0042326 | negative regulation of phosphorylation | 1.16e-03 |
| LATS2 | GO:0030111 | regulation of Wnt signaling pathway | 1.24e-03 |
| LATS2 | GO:0045936 | negative regulation of phosphate metabolic process | 1.76e-03 |
| LATS2 | GO:0010563 | negative regulation of phosphorus metabolic process | 1.76e-03 |
| LATS2 | GO:0043616 | keratinocyte proliferation | 1.76e-03 |
| LATS2 | GO:0042770 | signal transduction in response to DNA damage | 1.91e-03 |
| LATS2 | GO:0071479 | cellular response to ionizing radiation | 2.30e-03 |
| LATS2 | GO:0042368 | vitamin D biosynthetic process | 2.30e-03 |
| LATS2 | GO:0060536 | cartilage morphogenesis | 2.30e-03 |
| LATS2 | GO:0030330 | DNA damage respons | 4.35e-05 |
| LATS2 | GO:0051256 | mitotic spindle midzone assembly | 2.30e-03 |
| LATS2 | GO:0061314 | Notch signaling involved in heart development | 2.30e-03 |
| LATS2 | GO:0000022 | mitotic spindle elongation | 2.42e-03 |
| LATS2 | GO:0030656 | regulation of vitamin metabolic process | 2.42e-03 |
| LATS2 | GO:0072182 | regulation of nephron tubule epithelial cell differentiation | 2.42e-03 |
| LATS2 | GO:0042362 | fat-soluble vitamin biosynthetic process | 2.70e-03 |
| LATS2 | GO:0043086 | negative regulation of catalytic activity | 2.70e-03 |
| LATS2 | GO:0051231 | spindle elongation | 2.71e-03 |
| LATS2 | GO:0051255 | spindle midzone assembly | 2.71e-03 |
| LATS2 | GO:0072160 | nephron tubule epithelial cell differentiation | 2.71e-03 |
| LATS2 | GO:0001667 | ameboidal-type cell migration | 2.71e-03 |
| LATS2 | GO:0031669 | cellular response to nutrient levels | 2.71e-03 |
| LATS2 | GO:0001649 | osteoblast differentiation | 2.75e-03 |
| LATS2 | GO:0003198 | epithelial to mesenchymal transition involved in endocardial cushion formation | 2.75e-03 |
| LATS2 | GO:0043518 | negative regulation of DNA damage respons | 8.96e-05 |
| LATS2 | GO:2000696 | regulation of epithelial cell differentiation involved in kidney development | 2.97e-03 |
| LATS2 | GO:0071901 | negative regulation of protein serine/threonine kinase activity | 3.14e-03 |
| LATS2 | GO:0031668 | cellular response to extracellular stimulus | 3.44e-03 |
| LATS2 | GO:0060576 | intestinal epithelial cell development | 3.46e-03 |
| LATS2 | GO:0071900 | regulation of protein serine/threonine kinase activity | 3.46e-03 |
| LATS2 | GO:0006098 | pentose-phosphate shunt | 4.04e-03 |
| LATS2 | GO:0042359 | vitamin D metabolic process | 4.04e-03 |
| LATS2 | GO:0034504 | protein localization to nucleus | 4.44e-03 |
| LATS2 | GO:0060070 | canonical Wnt signaling pathway | 4.44e-03 |
| LATS2 | GO:0072234 | metanephric nephron tubule development | 4.44e-03 |
| LATS2 | GO:2000810 | regulation of bicellular tight junction assembly | 4.44e-03 |
| LATS2 | GO:0043588 | skin development | 4.44e-03 |
| LATS2 | GO:0097193 | intrinsic apoptotic signaling pathway | 4.46e-03 |
| LATS2 | GO:0006740 | NADPH regeneration | 4.48e-03 |
| LATS2 | GO:0072202 | cell differentiation involved in metanephros development | 4.48e-03 |
Top |
Related Drugs to WDFY2_LATS2 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning WDFY2-LATS2 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to WDFY2_LATS2 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |